key: cord-0919359-a7xh8ptg authors: Hadeler, Edward; Bray, Fleta title: Prescription Restrictions on Hydroxychloroquine Among the Largest Florida Pharmacy Chains During the COVID-19 Pandemic: An Observational Study date: 2020-05-22 journal: J Am Acad Dermatol DOI: 10.1016/j.jaad.2020.05.092 sha: afae52937c809c71d0a4cb0172799acfdf8c157b doc_id: 919359 cord_uid: a7xh8ptg nan Hydroxychloroquine has long been utilized by dermatologists in the treatment of chronic disease, 24 with use across such broad conditions as connective tissue disease, sarcoidosis, to lichen 25 planopilaris. The medication has generally enjoyed wide availability at a more affordable cost. 26 Earlier this year, hydroxychloroquine became a household name after political leaders touted the 27 drug's efficacy in the treatment and post-exposure prophylaxis of COVID-19. As demand for 28 hydroxychloroquine grew, pharmacies reported shortfalls in supply, and began implementing 29 restrictions on dispensation. 1 Our study seeks to characterize these restrictions in Florida-based 30 locations of the nation's most profitable retail pharmacies. 31 The six largest pharmacies with locations in Florida (CVS, Walgreens, Walmart, Humana, 32 Publix, Costco) and two mail order pharmacy companies (Cigna-Express Scripts, Optum Rx by 33 UnitedHealth) were identified based on total prescription dispensing revenue in 2019. 2 April 34 2020 policies regarding dispensation limits for new prescriptions of hydroxychloroquine and 35 prescription refills were obtained from online data, where available. Otherwise, dispensation 36 limits were obtained by phone from corporate offices, and, when redirected, confirmed with at 37 least 3 local pharmacists at different locations. 38 Restriction limitations, when applicable, for new hydroxychloroquine prescriptions and 39 prescription refills are summarized in Table 1 professional advice due to shortages. 3 50 A major concern lies in patients with new diagnoses of inflammatory and autoimmune 51 conditions that require new prescriptions of hydroxychloroquine, now subject to more stringent 52 quantity limits. Currently available data regarding the efficacy of hydroxychloroquine in the 53 treatment of COVID-19 is conflicting, 4,5 and the durability of this new indication for 54 hydroxychloroquine remains to be seen. If current market demand for hydroxychloroquine 55 continues to exceed supply, and large national shortages for hydroxychloroquine continue to 56 persist, subsequent prescription limitations may put dermatology patients at risk. Continued 57 efforts should be made to ensure medication is available for patients with chronic rheumatologic 58 and dermatologic conditions that require hydroxychloroquine, including upholding proper 59 prescribing practices by doctors. Dermatologists are called to self-police, and limit prescriptions 60 for hydroxychloroquine to those for dermatologic purposes. Dermatologists should also 61 anticipate increased clarification queries on ICD codes and imposed quantity limits, and will face 62 local variance in supply. Compounding and non-chain pharmacies may serve as supplementary 63 sources to meet increased demand. Dermatologists must be aware of, and adapt to, identifiable 64 changes in the market for hydroxychloroquine for the benefit of their patients. COVID-19 Prescribing **Last 73 2. 15 largest pharmacies in the US Experiences of Patients with Rheumatic Diseases in 76 the US During Early Days of the COVID-19 Pandemic. ACR Open Rheumatol Association of Treatment With 79 Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With 80 COVID-19 in Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin 83 alone: outcomes in hospitalized COVID-19 patients. medRxiv